Multiple Myeloma Posts on Medivizor

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Posted by Medivizor on May 8, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Apr 29, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Posted by Medivizor on Apr 10, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Posted by Medivizor on Apr 3, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness and safety of using daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (Decadron)(D-Rd) to lenalidomide and dexamethasone (Rd) treatment in patients with newly diagnosed multiple myeloma (NDMM), based on frailty levels. The data showed that D-Rd was more effective than Rd at improving...

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

$Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel$

Posted by Medivizor on Mar 15, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM). This study concluded that this treatment improves HR-QoL for these patients. Some...

Vacations for Adult Cancer Patients: Update

Posted by Peigi Chace on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Effects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma

$Effects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma$

Posted by Medivizor on Feb 13, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

Posted by Medivizor on Jan 23, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of bortezomib (BTZ; Velcade) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for improving relapse and chronic graft versus host disease (cGVHD) in patients with multiple myeloma (MM) that are young or high-risk. The data showed that BTZ maintenance is effective and safe in...

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Posted by Medivizor on Dec 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-based therapy for patients with multiple myeloma (MM) in a real-world setting. The data showed that daratumumab-based therapy in a real-world setting was not as effective as in clinical trials. Some background Multiple myeloma (MM) is a type of cancer that comes from...

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Posted by Medivizor on Dec 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) therapy for patients with newly diagnosed multiple myeloma (MM). The data showed that adding daratumumab to the lenalidomide and dexamethasone (Rd) regimen was safe and improved...

Effect of maintenance therapy after second AHCT in patients with multiple myeloma.

Posted by Medivizor on Dec 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study explored the role of maintenance therapy after a second autologous hematopoietic cell transplant (AHCT2) in patients with multiple myeloma (MM). The data showed that maintenance therapy after AHCT2 was associated with better outcomes in these patients. Some background MM is commonly hard-to-treat. Many patients are treated...

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Posted by Medivizor on Nov 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro) as maintenance therapy after bortezomib (Velcade)-based induction therapy in real-world patients with multiple myeloma (MM). The data showed that the outcomes of these patients in the real-world setting were good with manageable side effects. Some background...

Multiple Myeloma Posts on Medivizor

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

Vacations for Adult Cancer Patients: Update

Effects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Effect of maintenance therapy after second AHCT in patients with multiple myeloma.

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Categories

Recent Posts

Archives

Multiple Myeloma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email